As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones

Madrigal’s drug Rezdiffra has exceeded expectations, and the company plans to stay ahead of incoming competition with a highly targeted patient approach.

By Kelly Bilodeau • Nov. 19, 2025

Pharma’s clinical trial diversity push faces a new threat

Skyrocketing healthcare costs could deliver another blow to the industry’s ongoing quest to boost representation in R&D.

By Meagan Parrish • Nov. 7, 2025

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

Why a treatment older than the FDA is getting new regulatory scrutiny

MAHA-aligned patients and providers are pushing back to ensure access to an animal-derived thyroid hormone treatment.

By Kelly Bilodeau • Oct. 20, 2025

Pregnant women, long excluded from drug trials, are back in the spotlight

The White House has raised concerns around women’s health, but R&D on pregnant and breastfeeding women is still lacking.

By Meagan Parrish • Oct. 17, 2025

Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?

This week’s launch of subcutaneously administered Keytruda Qlex gives Merck a safety net for the cancer drug’s daunting patent cliff.

By Michael Gibney • Oct. 2, 2025

AstraZeneca’s at-home flu vaccine is a breakthrough that could pave the way for others

FluMist Home could be a test case for at-home vaccines against a backdrop of challenging regulatory shifts.

By Alexandra Pecci • Oct. 1, 2025

Top pharma industry conferences in 2026

Where pharma leaders will converge, discuss and navigate the industry’s shifting landscape in 2026.

By Meagan Parrish • Oct. 1, 2025

As obesity M&A heats up, pharmas could get ‘blinded by opportunity’

With companies racing to secure GLP-1-related assets, there may be risks for moving too fast.

By Kelly Bilodeau • Sept. 29, 2025

From atop Mt. Fuji, a Takeda team heralds a need for human plasma

The climb aimed to raise money and awareness as Takeda ramps up its plasma-derived therapy presence in Japan.

By Alexandra Pecci • Sept. 16, 2025

4 years from clinic to approval — Precigen’s ‘unprecedented’ FDA nod and what comes next

The company scored the first-ever approval to treat a potentially deadly infection leveraging its gene therapy platform.

By Meagan Parrish • Sept. 12, 2025

Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology.

Growing research suggests various ways weight loss drugs could have an impact in cancer care.

By Michael Gibney • Sept. 11, 2025

Inside pharma’s race to deliver new treatments for dwarfism

By targeting the underlying genetic mutation that drives the condition, researchers hope to increase height and address debilitating complications.

By Kelly Bilodeau • Sept. 8, 2025

At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves

Robert F. Kennedy Jr. faced criticism Thursday even from Republican lawmakers over changes to federal vaccine policy as well as a leadership crisis at the CDC.

By Delilah Alvarado , Jonathan Gardner • Sept. 5, 2025

Why an FDA decision for a new drug could ripple through the ultra-rare disease space

All eyes are on Stealth BioTherapeutics as it awaits a long-delayed approval for its first-in-class treatment for Barth syndrome.

By Alexandra Pecci • Aug. 26, 2025

As gene therapies falter on the market, this biopharma is aiming to defy the odds

After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.

By Meagan Parrish • Aug. 8, 2025

Novartis’ Zolgensma sales fall again as gene therapy market woes persist

Novartis has seen sales decline in a difficult gene therapy market. Is there hope on the horizon?

By Michael Gibney • July 22, 2025

Pricing watchdog will take on the rising cost of drugs at launch

ICER’s upcoming report could shed light on how the launch price of newly approved drugs affects overall cost and access from a patient perspective.

By Michael Gibney • July 10, 2025

GLP-1 roadblocks: Discontinuation rates soar as insurers clamp down

As more drugmakers aim for the lucrative weight loss market, patient challenges linger.

By Amy Baxter • July 7, 2025

A biopharma bolsters patient centricity and trial diversity goals through newly created role

Ardelyx’s newly minted chief patient officer is infusing patient experiences into every element of the business.

By Alexandra Pecci • July 1, 2025

Biogen scores Cannes Festival win with dark humored campaign

The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity.

By Alexandra Pecci • June 24, 2025

How a patient group tackled research diversity for one disease and triggered change for pharma

A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.

By Meagan Parrish • June 17, 2025

Will pharma finally score a policy win for 340B?

The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight.

By Kelly Bilodeau • June 16, 2025

A day in the life of GSK’s U.S. president

How Maya Martinez-Davis juggles life on the go during a busy year for new drug launches.

By Meagan Parrish • June 13, 2025

COVID vax restrictions may not hamper uptake — but the market is still under pressure

If insurers stop covering the shots and approvals become more restrictive, the most recent policy shifts could heap more challenges onto pharma’s vaccine space. 

By Alexandra Pecci • June 10, 2025

AbbVie’s ADC win shows how pharma can break through in solid tumors

 An oncology pivot recently paid off for the large pharma, which scored a milestone nod for its lead ADC.

By Meagan Parrish • May 30, 2025